Ordering
Available Variants1 mg
CHJ.32299-1mg
Price
€491.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
1 mg | CHJ.32299-1mg | €491.20 |
from Streptomyces hygroscopicus, ≥98% (HPLC), Nuclear hormone receptor inhibitor, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C29H40N2O9 |
|---|---|
| CAS Number | 30562-34-6 |
| Molecular Weight | 560.64 |
| UNSPSC Code | 12352200 |
| PubChem Substance ID | 329799914 |
| NACRES | NA.77 |
| MDL number | MFCD00274570 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 300 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 2 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Gloves, type N95 (US) |
Technical Overview & Applications Use-case context
Geldanamycin, a benzoquinone ansamycin antibiotic, is produced by the bacterium Streptomyces hygroscopicus and has been assigned the CAS number 30562-34-6. It exhibits a range of biological activities, including antitumor and antifungal properties, by inhibiting heat shock protein 90 (Hsp90), a molecular chaperone involved in signal transduction pathways. The compounds ability to bind to Hsp90 leads to the degradation of various client proteins, resulting in the disruption of cellular processes and ultimately inducing apoptosis in cancer cells. Geldanamycin has been extensively studied for its potential therapeutic applications, particularly in the treatment of cancer, and its derivatives have been developed to improve its pharmacological properties and reduce its toxicity. Further research is ongoing to fully explore the clinical potential of geldanamycin and its analogs.
